Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoporosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoporosis
    FDA: No Connection Between Oral Bisphosphonates, Atypical Subtrochanteric Femur Fractures - (DGNews)
    TopAbstracts in Osteoporosis 03/02/2010 - (DGNews)
    Lasofoxifene in postmenopausal women with osteoporosis - (N Engl J Med)
    Lasofoxifene Reduces Fracture Risk After 5 Years, But Increases Risk of VTE - (DGNews)
    TopAbstracts in Osteoporosis 02/16/2010 - (DGNews)

    News archive

     Recent webcasts/CME - Osteoporosis
      Anabolic Therapy for Osteoporosis
      Rheumatology Highlights Report Post 2009 National Meeting - Metabolic Bone Disease
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Osteoporotic Spinal Compression Fractures
      Metabolic Bone Disease

      Webcasts/CME archive

       Recent cases - Osteoporosis
        Bilateral Pathological Hip Fractures In A Patient With A Bipulmonary Transplant: A Case Report
        Subcapital Femoral Neck Fracture After Fixation Of An Intertrochanteric Fracture With A Proximal Femoral Nail: A Report Of Two Cases
        A Productive Cough
        Operative Management of a Subtrochanteric Fracture in Severe Osteoporosis: A Case Report
        Bilateral Femoral Neck Fractures Due to Transient Osteoporosis of Pregnancy: A Case Report

        Cases archive
          




        my personal edition > osteoporosis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Forteo (human teriparatide parathyroid hormone) a Potential Treatment for High Risk Fracture Patients with Osteoporosis

        A DGReview of :"Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis"
        Cleveland Clinic Journal of Medicine

        07/23/2003
        By Deanna M. Green


        Forteo (human teriparatide parathyroid hormone, PTH 1-24) is a genetically engineered anabolic drug that increases bone mass and decreasing fracture risk in postmenopausal women with osteoporosis and is currently recommended for patients with a high risk of fracture, according to a recent American review.

        Traditional treatments of osteoporosis include antiresorptive drugs that inhibit osteoclast bone resorption, such as oestrogen, selective oestrogen receptor modulators, bisphosphonates, and calcitonin.

        The new genetically engineered drug is now available and approved in the United States by the Food and Drug Administration for treatment of osteoporosis. It is a recombinant form of the parathyroid hormone, which naturally regulates calcium in the body. It uses a different mode of action for treating osteoporosis than the antiresorptive agents in that it increases bone turnover and stimulates osteoblasts.

        Chad Deal, MD, and James Gideon, MD, PhD, with the Cleveland Clinic Foundation, Cleveland, Ohio, United States, and Eli Lilly and Company, reviewed the pharmacology and efficacy of Forteo.

        In a clinical trial funded by Eli Lilly and Company, the researchers compared the efficacy of Forteo 20 mcg or 40 mcg daily for an average 19 months in comparison and placebo in 1,637 postmenopausal women with low bone mass and prior vertebral fractures.

        Results show that bone density increased and fracture risk decreased to a greater extent in the Forteo-treated group than in the placebo group. An 18-month follow up study also found that the protective effect persisted even after cessation of treatment.

        Side effects associated with Forteo treatment include leg cramps, dizziness, and hypercalcaemia. Reports that Forteo also caused osteosarcoma in rats have not been confirmed in humans.

        Forteo is not recommended for patients with open epiphyses, such as children, teenagers and young adults, and patients with Paget disease, metabolic bone diseases, primary hyperparathyroidism, history of osteosarcoma, and renal impairment.

        The authors recommend using the drug "as initial therapy for 2 years (the FDA-approved interval) in high-risk patients, followed by an antiresorptive agent to maintain and further the increase in bone mass achieved with Forteo." For patients already taking antiresorptive agents, he recommends stopping this treatment before starting Forteo.

        They add, "the drug is much more expensive than antiresorptive agents," ($600 a month for treatment) and will therefore likely be restricted to patients with high fracture risk that can pay or have insurance coverage for the treatment.
        Cleveland Clinic Journal of Medicine 2003;70:7:585-601. "Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send